A protein-building molecule helped switch resistant prostate tumors back into a drug-sensitive state in experimental models, offering a potential target for future treatments. Many treatments for prostate cancer, one of the most common cancers in men, target a protein called…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.